Global Antisense and RNAi Therapeutics Market Share

Statistics for the 2023 & 2024 Global Antisense and RNAi Therapeutics market share, created by Mordor Intelligence™ Industry Reports. Global Antisense and RNAi Therapeutics share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Global Antisense and RNAi Therapeutics Industry

The antisense and RNAi therapeutics market is consolidated in nature due to the presence of a limited number of companies operating across the globe. The competitive landscape includes an analysis of a few international as well as local companies that operate in the market such as Alnylam Pharmaceuticals, Inc., Biogen Inc., Ionis Pharmaceuticals (Akcea Therapeutics, Inc.), Sarepta Therapeutics, Inc., Novartis AG, Silence Therapeutics, Arbutus Biopharma (Formerly Called Tekmira Pharmaceuticals), Isarna Therapeutics GmbH, Gene Signal International SA, Arrowhead Pharmaceuticals, Inc., and Benitec Biopharma Ltd, among others.

Antisense & RNAi Therapeutics Market Leaders

  1. Alnylam Pharmaceuticals, Inc.

  2. Biogen Inc.

  3. Ionis Pharmaceuticals (Akcea Therapeutics, Inc.)

  4. Sarepta Therapeutics, Inc.

  5. Novartis AG

*Disclaimer: Major Players sorted in no particular order

Antisense and RNAi Therapeutics Market Concentration

Antisense & RNAi Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)